Merck & Co. (MRK) Insider Sells €2,532,456.00 in Stock
Merck & Co. (NYSE:MRK) insider Weir Mirian M. Graddick sold 40,800 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the sale, the insider now directly owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Merck & Co. (NYSE:MRK) opened at 62.46 on Wednesday. The company has a 50-day moving average price of $62.71 and a 200-day moving average price of $58.27. The company has a market capitalization of $172.71 billion, a PE ratio of 34.26 and a beta of 0.68. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.02. The business earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 earnings per share. Analysts predict that Merck & Co. will post $3.75 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. Merck & Co.’s dividend payout ratio (DPR) is 101.10%.
Institutional investors have recently bought and sold shares of the company. Accredited Investors Inc. boosted its stake in Merck & Co. by 0.3% in the first quarter. Accredited Investors Inc. now owns 9,125 shares of the company’s stock worth $483,000 after buying an additional 23 shares in the last quarter. Thomaspartners Inc. boosted its stake in Merck & Co. by 0.3% in the first quarter. Thomaspartners Inc. now owns 9,024 shares of the company’s stock worth $477,000 after buying an additional 26 shares in the last quarter. QCI Asset Management Inc. NY boosted its stake in Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock worth $137,000 after buying an additional 27 shares in the last quarter. Vicus Capital boosted its stake in Merck & Co. by 0.3% in the first quarter. Vicus Capital now owns 11,121 shares of the company’s stock worth $588,000 after buying an additional 37 shares in the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management boosted its stake in Merck & Co. by 0.8% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 4,738 shares of the company’s stock worth $250,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 72.93% of the company’s stock.
Several analysts recently issued reports on the stock. Argus reissued a “buy” rating and issued a $65.00 price target on shares of Merck & Co. in a research report on Wednesday, September 14th. Morgan Stanley set a $60.00 price target on shares of Merck & Co. and gave the company a “hold” rating in a research report on Tuesday, September 13th. Jefferies Group reissued a “hold” rating and issued a $56.00 price target (down previously from $57.00) on shares of Merck & Co. in a research report on Monday, September 12th. Berenberg Bank reissued a “hold” rating and issued a $62.00 price target on shares of Merck & Co. in a research report on Sunday, September 11th. Finally, Barclays PLC lifted their price target on shares of Merck & Co. from $66.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, September 9th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Merck & Co. has a consensus rating of “Hold” and a consensus target price of €63.20 ($70.23).
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.